Contact Us
Drug Search Results
More Filters [+]

MEDI-575

Alternative Names: medi-575, medi575, medi 575
Latest Update: 2021-05-01
Latest Update Note: PubMed Publication

Product Description

Tovetumab (MEDI-575) is a fully human IgG2_ monoclonal antibody that specifically binds to human platelet-derived growth factor receptor alpha (PDGFR_) and blocks receptor signal transduction by PDGF ligands. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33210183/)

Mechanisms of Action: PGFR Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MEDI-575

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Glioblastoma

Phase 1: Hepatocellular Carcinoma|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CD-ON-MEDI-575-1031

P2

Terminated

Non-Small-Cell Lung Cancer

2013-09-11

2010-023854-35

P2

Terminated

Non-Small-Cell Lung Cancer

2013-07-10

CD-ON-MEDI-575-1042

P2

Completed

Glioblastoma

2012-11-01

D2840C00001

P1

Completed

Hepatocellular Carcinoma

2012-11-01

Recent News Events

Date

Type

Title

05/01/2021

PubMed

 Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells.

11/18/2020

PubMed

 A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions